In vitro and in vivo degradation of an injectable bone repair composite

In vitro and in vivo degradation behaviors of an injectable bone regeneration composite (IBRC) which comprised of nano-hydroxyapatite/collagen (nHAC) particles in alginate hydrogel carrier were investigated. In vitro degradation quantitative testing indicated that the alginate had a faster degradation rate in simulated body fluid (SBF) than in deionized water at 37 °C. Similarly, IBRC also had a higher degradation rate in SBF than in deionized water at 37 °C, which was evaluated by alginate molecular weight measurement, mechanical properties test and degradation kinetics evaluation. But molecular weight of alginate degraded slower in IBRC than that in aqueous solution. In vitro results showed that degradation medium SBF had influence on degradation of alginate molecules. In the in vivo degradation study, surprisingly, there was no obvious decreasing of molecular weight of alginate from 0 to 8 weeks. IBRC degraded mostly after 24 weeks implantation and was replaced by connective tissue. No fibrous capsule and acute inflammatory reaction were found during the observed 24 weeks after IBRC implantation. There is only a mild short-term inflammatory response in rat dorsum muscle. These results indicated that IBRC had a controllable degradability and biocompatibility. Therefore, IBRC may be a promising degradable material for bone repair and bone tissue engineering.